

REMARKS

Reconsideration is requested.

Claims 1-75, 83, 85, 87, 89, 91, 93, 95, 97, 99 and 105-108, have been canceled, without prejudice. Claims 76-80 and 101-103 have been allowed. Claims 109-111 have been added and find support throughout the specification, such as at page 2, line 27 to page 3, line 6. No new matter has been added. Claims 76-82, 84, 86, 88, 90, 92, 94, 96, 98, 100-104 and 109-111 are pending. The claims are submitted to be in condition for allowance for the reasons noted herein.

The Examiner is requested to acknowledge the applicants claim for domestic priority in the Examiner's next Action.

Return of an initialed copy of the PTO-1449 Form filed with the Information Disclosure Statement dated April 1, 2002, is requested with the Examiner's next Action, pursuant to MPEP § 609. The undersigned notes the PTO-1449 Form lists documents cited in the International Search Report relating to the parent application No. PCT/US00/26797. The Notice of Acceptance dated November 12, 2002, indicates the Patent Office has received copies of the cited references. The Examiner is requested to contact the undersigned however if anything further is required in this regard.

The pending claims are directed to the subject matter of the Examiner's Group I stated on page 2 of the Office Action dated September 15, 2003 (Paper No. 10). Withdrawn claims have been canceled, without prejudice, to advance prosecution.

The Section 112, second paragraph, rejection of claims 81-83, 94-99 and 104 has been obviated by the above amendments.

Specifically, the inadvertent typographical error in claim 81 has been corrected according to the Examiner's suggestion. Claim 83 has been canceled, without prejudice. Claim 95 has been canceled, without prejudice. Claims 82 and 94 have been amended to remove the objected-to recitation of "the medicament". Claim 97 has been canceled, without prejudice. Claim 99 has been canceled, without prejudice. Claim 94 has been amended to provide proper antecedent basis for claims 96 and 98. Claim 104 has been amended to respond to the Examiner's comment on page 4 of Paper No. 10. Claim 104 is submitted to be definite.

Withdrawal of the Section 112, second paragraph, rejection of claims 81-83, 94-99 and 104 is requested.

The Section 102 rejection of claim 104 over Naviaux (133:187987CA) or Shanahan-Prendergast (137:88442CA) is, to the extent not obviated by the above, traversed. Reconsideration and withdrawal of the rejection are requested in view of the following distinguishing comments.

Naviaux and Shanahan-Prendergast each refer to Brequinar which was said to be useful in the treatment of mitochondrial disorders (Naviaux) or in the treatment of neoplasia, particular resistant neoplasia and immune disregulatory disorders (Shanahan-Prendergast).

Claim 104 refers to the compounds of formula (IIa), based on the passage of the description at pages 13 to 14. These compounds are novel. The use of these compounds as anti-flavivirus, anti-rhabdovirus or antiparamyxovirus agents is also submitted to be novel and patentable over the cited art.

TAN et al
Appl. No. 10/089,553
December 15, 2003

Reconsideration and withdrawal of the Section 102 rejection of claim 104 is requested.


The claims are submitted to be in condition for allowance and a Notice to that effect is requested.

The Examiner is requested to contact the undersigned if anything further is required in this regard.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:



B. J. Sadoff
Reg. No. 36,663

BJS:plb
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100